Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy.

Pharmacogenomics - 1 Apr 2020

Rumiato Enrica, Boldrin Elisa, Malacrida Sandro, Battaglia Giorgio, Sileni Vanna Chiarion, Ruol Alberto, Amadori Alberto, Saggioro Daniela

Abstract excerpt

Aim: Clinical features of esophageal cancer (EC) patients have poor prognostic power. Thus, it is paramount to discover biomarkers that can allow a more accurate survival prediction. Methods: To detect genetic variants associated with survival, DNA from 120 patients treated with cisplatin-based neoadjuvant therapy were genotyped using drug metabolism enzymes and transporters array. Results: We identified two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Follow-Up Studies

Share to Neoadjuvant Therapy

Share to Organic Cation Transporter 1

Share to PPAR delta

Share to Survival Rate

Source

Identifiers

PMID: 32285752
DOI: 10.2217/pgs-2019-0165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy.PMID 32285752Read ↗

A germline predictive signature of response to platinum chemotherapy in esophageal cancer.Semantic proximity Read ↗

Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy.Semantic proximity Read ↗

A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.Semantic proximity Read ↗

Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.Semantic proximity Read ↗

Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.Semantic proximity Read ↗

ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.Semantic proximity Read ↗

Genetic variations in esophageal cancer risk and prognosis.Semantic proximity Read ↗

Genetic variants in nucleotide excision repair pathway predict survival of esophageal squamous cell cancer patients receiving platinum-based chemotherapy.Semantic proximity Read ↗

Genetic variants in DNA repair predicts the survival of patients with esophageal cancer.Semantic proximity Read ↗

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.Semantic proximity Read ↗

Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer.Semantic proximity Read ↗

GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.